Cargando…
Mechanism of angiotensin-converting enzyme inhibitors in the treatment of dilated cardiomyopathy based on a protein interaction network and molecular docking
BACKGROUND: Dilated cardiomyopathy (DCM) is a severe manifestation or intermediate stage of cardiovascular disease progression with a significantly poor prognosis. Based on a protein interaction network and molecular docking, the present study determined the genes and mechanism of action of angioten...
Autores principales: | Zhong, Guofu, Chen, Chunxiao, Wu, Shixin, Chen, Junteng, Han, Yue, Zhu, Qinghua, Xu, Mujuan, Nie, Qinqi, Wang, Ling |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315431/ https://www.ncbi.nlm.nih.gov/pubmed/37405022 http://dx.doi.org/10.21037/cdt-23-112 |
Ejemplares similares
-
The appropriate dose of angiotensin‐converting‐enzyme inhibitors or angiotensin receptor blockers in patients with dilated cardiomyopathy. The higher, the better?
por: Ishida, Junichi, et al.
Publicado: (2015) -
Considerations for Docking of Selective Angiotensin-Converting Enzyme Inhibitors
por: Caballero, Julio
Publicado: (2020) -
Impact of Angiotensin I Converting Enzyme Insertion/Deletion Polymorphisms on Dilated Cardiomyopathy and Hypertrophic Cardiomyopathy Risk
por: Yang, Jianmin, et al.
Publicado: (2013) -
The use of angiotensin II receptor blocker is associated with greater recovery of cardiac function than angiotensin‐converting enzyme inhibitor in dilated cardiomyopathy
por: Enzan, Nobuyuki, et al.
Publicado: (2022) -
The complete reversal effect following angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and beta-blockers after the primary diagnosis of dilated cardiomyopathy
por: Liu, Tao, et al.
Publicado: (2023)